EA201201294A1 - Гидрат гидрохлорида агомелатина и его получение - Google Patents

Гидрат гидрохлорида агомелатина и его получение

Info

Publication number
EA201201294A1
EA201201294A1 EA201201294A EA201201294A EA201201294A1 EA 201201294 A1 EA201201294 A1 EA 201201294A1 EA 201201294 A EA201201294 A EA 201201294A EA 201201294 A EA201201294 A EA 201201294A EA 201201294 A1 EA201201294 A1 EA 201201294A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrate
hydrochloride
agomelatine
ahomelatin
obtaining
Prior art date
Application number
EA201201294A
Other languages
English (en)
Other versions
EA022067B1 (ru
Inventor
Ханьбинь Шань
Чжедун Юань
Сюэянь Чжу
Пэн Чжан
Хунюань Пань
Сюй Юй
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44599556&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA201201294A1 publication Critical patent/EA201201294A1/ru
Publication of EA022067B1 publication Critical patent/EA022067B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Abstract

Изобретение относится к гидрату гидрохлорида агомелатина формулы (I), его получению и применению и к фармацевтической композиции, содержащей его. Гидрат гидрохлорида агомелатина, полученный настоящим способом, обладает значительно увеличенной растворимостью по сравнению с агомелатином и таким образом является более подходящим для производства фармацевтических составов. К тому же, продукт обладает большей стабильностью и чистотой. Применяя настоящий способ, может быть получен продукт высокой чистоты простым способом без каких-либо усложняющих стадий. Представлен гидрат гидрохлорида агомелатина формулы (I)в которой Х означает Cl.
EA201201294A 2010-03-17 2011-03-17 Гидрат гидрохлорида агомелатина и его получение EA022067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201010126254XA CN102190594A (zh) 2010-03-17 2010-03-17 阿戈美拉汀氯化氢水合物及其制备方法
PCT/CN2011/071910 WO2011113362A1 (en) 2010-03-17 2011-03-17 Agomelatine hydrochloride hydrate and preparation thereof

Publications (2)

Publication Number Publication Date
EA201201294A1 true EA201201294A1 (ru) 2013-04-30
EA022067B1 EA022067B1 (ru) 2015-10-30

Family

ID=44599556

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201294A EA022067B1 (ru) 2010-03-17 2011-03-17 Гидрат гидрохлорида агомелатина и его получение

Country Status (36)

Country Link
US (1) US8729131B2 (ru)
EP (1) EP2547649B1 (ru)
JP (1) JP5634532B2 (ru)
KR (1) KR101406727B1 (ru)
CN (2) CN102190594A (ru)
AP (1) AP2012006492A0 (ru)
AU (1) AU2011229618B2 (ru)
BR (1) BR112012023317B1 (ru)
CA (1) CA2792417C (ru)
CL (1) CL2012002540A1 (ru)
CR (1) CR20120462A (ru)
CU (1) CU20120137A7 (ru)
CY (1) CY1116086T1 (ru)
DK (1) DK2547649T3 (ru)
EA (1) EA022067B1 (ru)
EC (1) ECSP12012155A (ru)
ES (1) ES2530772T3 (ru)
GE (1) GEP20156231B (ru)
GT (1) GT201200259A (ru)
HK (1) HK1177451A1 (ru)
HR (1) HRP20150071T1 (ru)
IL (1) IL221782A (ru)
MA (1) MA34055B1 (ru)
ME (1) ME02054B (ru)
MX (1) MX2012010541A (ru)
NI (1) NI201200140A (ru)
NZ (1) NZ602450A (ru)
PE (1) PE20130013A1 (ru)
PL (1) PL2547649T3 (ru)
PT (1) PT2547649E (ru)
RS (1) RS53815B1 (ru)
SG (1) SG183868A1 (ru)
SI (1) SI2547649T1 (ru)
TN (1) TN2012000435A1 (ru)
UA (1) UA105425C2 (ru)
WO (1) WO2011113362A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013170738A1 (zh) * 2012-05-14 2013-11-21 上海右手医药科技开发有限公司 阿戈美拉汀酸根复合物及其制备方法和用途
CN102702041B (zh) * 2012-05-14 2013-08-14 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
CN102718676B (zh) * 2012-06-26 2014-04-09 福建广生堂药业股份有限公司 阿戈美拉汀硫酸盐及其制备方法
EP2934502A1 (en) 2012-12-21 2015-10-28 Laboratorios Lesvi S.L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2015013865A1 (en) * 2013-07-29 2015-02-05 Les Laboratoires Servier Agomelatine sulfonic acids complexes and preparation thereof
KR101470794B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
MA50817B1 (fr) 2015-07-02 2021-10-29 Acerta Pharma Bv Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
US10367757B2 (en) * 2016-08-27 2019-07-30 Nicira, Inc. Extension of network control system into public cloud

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PL366150A1 (en) * 2000-10-30 2005-01-24 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2934859B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
WO2012046253A2 (en) * 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms

Also Published As

Publication number Publication date
KR20120128712A (ko) 2012-11-27
PL2547649T3 (pl) 2015-04-30
SG183868A1 (en) 2012-10-30
BR112012023317B1 (pt) 2021-07-06
AP2012006492A0 (en) 2012-10-31
BR112012023317A2 (pt) 2016-05-24
PE20130013A1 (es) 2013-01-26
MX2012010541A (es) 2012-10-05
CY1116086T1 (el) 2017-02-08
SI2547649T1 (sl) 2015-03-31
ME02054B (me) 2015-05-20
NZ602450A (en) 2014-12-24
CN102190594A (zh) 2011-09-21
CL2012002540A1 (es) 2013-01-11
NI201200140A (es) 2012-11-09
EP2547649A1 (en) 2013-01-23
CN102958911B (zh) 2015-11-25
KR101406727B1 (ko) 2014-06-13
RS53815B1 (en) 2015-06-30
CA2792417A1 (en) 2011-09-22
EP2547649A4 (en) 2013-09-04
GT201200259A (es) 2013-12-03
UA105425C2 (ru) 2014-05-12
EA022067B1 (ru) 2015-10-30
ECSP12012155A (es) 2012-12-28
JP2013522241A (ja) 2013-06-13
EP2547649B1 (en) 2014-11-19
CA2792417C (en) 2015-11-24
CU20120137A7 (es) 2012-11-15
CR20120462A (es) 2012-10-05
US20130005820A1 (en) 2013-01-03
ES2530772T3 (es) 2015-03-05
IL221782A (en) 2017-11-30
CN102958911A (zh) 2013-03-06
DK2547649T3 (en) 2015-03-02
JP5634532B2 (ja) 2014-12-03
US8729131B2 (en) 2014-05-20
MA34055B1 (fr) 2013-03-05
AU2011229618B2 (en) 2014-05-22
HRP20150071T1 (en) 2015-02-27
AU2011229618A1 (en) 2012-09-27
TN2012000435A1 (en) 2014-01-30
HK1177451A1 (zh) 2013-08-23
WO2011113362A1 (en) 2011-09-22
PT2547649E (pt) 2014-12-29
GEP20156231B (en) 2015-01-26

Similar Documents

Publication Publication Date Title
EA201201294A1 (ru) Гидрат гидрохлорида агомелатина и его получение
MY160460A (en) Agomelatine hydrochloride hydrate and preparation thereof
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
EA201101208A1 (ru) Гидрогалогенидный комплекс агомелатина и его получение
MD20140072A2 (ru) Новые пиррольные соединения, способ их получения и содержащие их фармацевтические композиции
IN2014MN02106A (ru)
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201490357A1 (ru) Индазолы
MD20140136A2 (ru) Ингибиторы вируса гепатита С
IN2014CN04530A (ru)
EA201301181A1 (ru) Триазолопиридины
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201691538A1 (ru) Способ получения солей вортиоксетина
EA201891804A1 (ru) Тетрациклиновые соединения
EA201391721A1 (ru) Способ получения полиморфной формы i эторикоксиба
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
IN2011KN05169A (ru)
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
MX355552B (es) Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.
IN2013DN02555A (ru)